AGO recommendations for diagnosis and treatment of patients with early breast cancer: Update 2013

Breast Care

Volumn 8, Issue 3, 2013, Pages 174-180

  Scharl, Anton ^a   Thomssen, Christoph ^b   Harbeck, Nadia ^c   Müller, Volkmar ^d  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b Frauenklinik Klinikum Amberg   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; EARLY CANCER; HUMAN; INTRADUCTAL CARCINOMA; MAMMOGRAPHY; PARTIAL MASTECTOMY; PLASTIC SURGERY; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PUBLICATION; TRIPLE NEGATIVE BREAST CANCER;

EID: 84880716196     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000353617     Document Type: Article

References (46)

1. CEBM: www.cebm.net/index.aspx?o = 1025 (download 20-5-13)
2. AGO Kommission Mamma: www.ago-online.de/de/ fuer-mediziner/leitlinien/mamma/
3. Hammond MEH, Hayes DF, Dowsett M, et al.: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28:2784-2795
4. Wolff AC, Hammond MEH, Schwartz JN, et al.: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145
5. Kennecke HF, Speers CH, Ennis CA, Gelmon K, Olivotto IA, Hayes M: Impact of routine pathology review on treatment for node-negative breast cancer. J Clin Oncol 2012;30:2227-2231
6. Vestjens JHMJ, Pepels MJ, et al.: Relevant impact of central pathology review on nodal classification in individual breast cancer patients. Ann Oncol 2012;23:2561-2566
7. Simon RM, Paik S, Hayes DF: Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009; 101:1446-1452
8. Paik S, Shak S, Tang G, et al.: A multigene assay to predict recurrence of tamoxifen-treated, nodenegative breast cancer. N Engl J Med 2004;351: 2817-2826
9. Paik S, Tang G, Shak S, et al.: Gene expression and benefit of chemotherapy in women with nodenegative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-3734
10. Filipits M, Rudas M, Jakesz R, et al.: A new molecular predictor of distant recurrence in ERpositive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 2011;17:6012-6020
11. Van't Veer LJ, Dai H, van de Vijver MJ, et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-536
12. Parker JS, Mullins M, Cheang MCU, et al.: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160-1167
13. Robert Koch Institut: Krebs in Deutschland 2007/2008. 8. Ausgabe. Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg). Berlin, 2012, pp. 64
14. Shaitelman SF, Wilkinson JB, Kestin LL, Ye H, Goldstein NS, Martinez AA, Vicini FA: Long-term outcome in patients with ductal carcinoma in situ treated with breast-conserving therapy: implications for optimal follow-up strategies. Int J Radiat Oncol Biol Phys 2012;83:e305-12
15. Staley H, McCallum I, Bruce J: Postoperative tamoxifen for ductal carcinoma in situ. Cochrane Database Syst Rev 2012;10:CD007847
16. Alba E, Chacon JI, Lluch A, Anton A, Estevez L, Cirauqui B, Carrasco E, Calvo L, Segui MA, Ribelles N, Alvarez R, Sanchez-Muñoz A, Sanchez R, Garcia-Asenjo JA, Rodriguez-Martin C, Escudero MJ, Albanell J: A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. Breast Cancer Res Treat 2012;136:487-493
17. Von Minckwitz G: Neoadjuvant chemotherapy in breast cancer-insights from the German experience Breast Cancer 2012;19:282-288
18. Kuehn T, Bauerfeind IGP, Fehm T, Fleige B, Helms G, Lebeau A, Liedtke C, von Minckwitz G, Nekljudova V, Schrenk P, Staebler A, Untch M: Sentinel lymph node biopsy before or after neoadjuvant chemotherapy-final results from the prospective german, multiinstitutional Sentinatrial. SABCS 2012, S2-2. Cancer Res 2012;72(24 suppl):89s
19. Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Flippo-Morton TS, Byrd DR, Ollila DW, Julian TB, McLaughlin SA, McCall L, Symmans WF, Le-Petross HT, Haffty BG, Buchholz TA, Hunt KK: The role of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4, N1-2) who receive neoadjuvant chemotherapy-results from the ACOSOG Z1071 trial. SABCS 2012, S2-1. Cancer Res 2012;72(24 suppl):89s
20. Mamounas EP, Anderson SJ, Dignam JJ, Bear HD, Julian TB, Geyer CE Jr, Taghian A, Wickerham DL, Wolmark N: Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol 2012;30:3960-3966
21. Brunnert KE: The Osnabrueck experience with reconstruction of the partial mastectomy defect; in Spear SL (ed): Surgery of the Breast, 3rd ed. Philadelphia, PA, Lippincott Williams & Wilkins, 2011, pp. 177-197
22. Huober J, von Minckwitz G: Neoadjuvant therapy-what have we achieved in the last 20 years? Breast Care (Basel) 2011;6:419-426
23. Houssami N: Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with BCT. Eur J Cancer 2010;46:3219
24. Lanitis S, Tekkis PP, Sgourakis G, Dimopoulos N, Al Mufti R, Hadjiminas DJ: Comparison of skinsparing mastectomy versus non-skin-sparing mastectomy for breast cancer: A meta-analysis of observational studies. Ann Surg 2010;251:632-639
25. Nava MB, Pennati AE, Lozza L, Spano A, Zambetti M, Catanuto G: Outcome of different timings of radiotherapy in implant-based breast reconstructions. Plast Reconstr Surg 2011;128:353-359
26. Peled AW, Foster RD, Esserman LJ, Park CC, Hwang ES, Fowble B: Increasing the time to expander-implant exchange after postmastectomy radiation therapy reduces expander-implant failure. Plast Reconstr Surg 2012;130:503-509
27. Salzberg CA: Focus on technique: one-stage implant-based breast reconstruction. Plast Reconstr Surg 2012;130(5 suppl 2):95S-103S
28. Seth AK, Hirsch EM, Kim JY, Fine NA: Long-term outcomes following fat grafting in prosthetic breast reconstruction: A comparative analysis. Plast Reconstr Surg 2012;130:984-989
29. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; for the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group: Long-term effects of continuing adjuvant tamoxifen to years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2012;pii:S0140-6736(12)61963-1
30. Metzger O, Giobbie-Hurder A, Mallon E, et al.: Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial. SABCS 2012;abstr S1-1
31. Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, Regan M, Sainsbury R: LHRHagonists in Early Breast Cancer Overview group. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: A meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007; 369:1711-1723
32. Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C, Wang YC, Bergh J, Di Leo A,. Swain S, Piccart M, Pritchard; Early Breast Cancer Trialists' group (EBCTCG): Comparison between different polychemotherapy regimes for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012;379:432-444
33. Shao N, Wang S, Yao C, Xu X, Thang Y, Zhang Y, Lin Y: Sequential versus concurrent anthracyclines and taxanes as adjuvant chemotherapy of early breast cancer: A meta-analysis of phase III randomized control trials. Breast 2012;21:389-393
34. Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, Steger G, Suter T, Toi M, Parmar M, Bubuteishvili-Pacaud L, Henschel V, Laeufle R, Bell R: Primary results of BEATRICE, a randomized phase III trial evaluating adjuvant bevacizumab-containing therapy in triple-negative breast cancer. SABCS 2012;abstr S6-5
35. Haviland JS, Agrawal R, Aird E, et al., on behalf of the START Trialists: The UK START (Standardisation of Breast Radiotherapy) trials: 10-year follow-up results. SABCS 2012;abstr S4-1
36. Herbert C, Nichol A, Olivotto I, et al.: The impact of hypofractionated whole breast radiotherapy on local relapse in patients with grade 3 early breast cancer: A population-based cohort study. Int J Radiat Oncol Biol Phys 2012;82:2086-2092
37. James ML, Lehman M, Hider PN, et al.: Fraction size in radiation treatment for breast conservation in early breast cancer. Cochrane Database Syst Rev 2010;CD003860
38. Njeh CF, Saunders MW, Langton CM: Accelerated partial breast irradiation using external beam conformal radiation therapy: A review. Crit Rev Oncol Hematol 2012;81:1-20
39. Hattangadi JA, Taback N, Neville BA, Harris JR, Punglia RS: Accelerated partial breast irradiation using brachytherapy for breast cancer: patterns in utilization and guideline concordance. J Natl Cancer Inst 2012;104:29-41
40. Vaidya JS, Wenz F, Bulsara M, et al.: Targeted intraoperative radiotherapy for early breast cancer: TARGIT-A trial-updated analysis of local recurrence and first analysis of survival. SABCS 2012;abstr S4-2
41. Bartelink H, Bourgier C, Elkhuizen P: Has partial breast irradiation by IORT or brachytherapy been prematurely introduced into the clinic? Radiother Oncol 2012;104:139-142
42. Freedman GM, Anderson PR, Bleicher RJ, et al.: Five-year local control in a phase II study of hypofractionated intensity modulated radiation therapy with an incorporated boost for early stage breast cancer. Int J Radiat Oncol Biol Phys 2012;84:888-893
43. Holmberg L, Anderson H; HABITS steering and data monitoring committees: HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomised comparison: trial stopped. Lancet 2004;363:453-455
44. Fahlén M, Fornander T, Johansson H, Johansson U, Rutqvist LE, Wilking N, von Schoultz E: Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer 2013;49:52-59
45. Bokmand S, Flyger H: Acupuncture relieves menopausal discomfort in breast cancer patients: A prospective, double blinded, randomized study. Breast 2013;22:320-323
46. Molassiotis A, Bardy J, Finnegan-John J, Mackereth P, Ryder DW, Filshie J, Ream E, Richardson A: Acupuncture for cancer-related fatigue in patients with breast cancer: A pragmatic randomized controlled trial. J Clin Oncol 2012; 30:4470-4476.